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 ABSTRACT
The distribution of such a scarce resource as deceased donor kidneys should be made by observing a balance 
between fairness, efficiency and flexibility. Before implementing a new kidney allocation system, these principles 
should be evaluated and assured objectively.
In this article we compare the renal transplant donor-recipient pair selection system implemented in Portugal 
in 2007 with the Eurotransplant (ET) and United Kingdom (UK) systems.
We simulated data for 500 waitlist kidney transplant candidates and 70 deceased donors. Each of the 70 
donors was allocated to the best pair of listed candidates, taking into account the criteria of the three allocation 
systems under analysis. Subsequently, we compare the selected candidate’s groups to kidney transplant.
The Portuguese organ allocation model selects candidates with a greater number of incompatibilities with the donor 
compared to the other two models. Under the Portuguese system’s rules, candidates have a greater age difference 
with the respective donors (median = 12.5 years) than those selected by the ET system (10 years) or the UK system 
(8 years). The Portuguese model selected more hypersensitized candidates (15%), but this difference was not statisti-
cally significant when compared to the percentage of hypersensitized patients selected by the ET model (10.7%).
The Portuguese model has less equity than the other two models under analysis, since the observed disad-
vantages regarding the number of incompatibilities and age differences with the respective donor are not com-
pensated for by the selection of patients with longer time on dialysis.
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 INTRODUCTION
When possible, renal transplantation is the best renal 
replacement therapy available for end stage renal dis-
ease patients. Transplantation is associated with a lower 
risk of death than is dialysis1.
In 2009, Portugal registered the highest number of 
performed kidney transplants in its history both in 
absolute terms2 and in relative terms compared with 
the remaining countries in the European Union (EU)3. 
In that year, Portugal reached first position within 28 
EU members’ ranking of kidney transplants per million 
inhabitants. Afterwards and until 2014, Portugal con-
secutively fell in this ranking, but 2015 saw a reversal 
of this trend,3 one we hope will continue in forthcoming 
years.
A kidney allocation system, in addition to being 
transparent, must seek a balance between fairness, 
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efficiency and flexibility in the distribution of these 
organs. The efficiency criterion allocates kidneys looking 
for the greatest good for the greatest number of 
patients; using a fairness criterion kidneys would be 
allocated to those patients who need them the most4. 
In other words, the candidates chosen as possible 
donors should be those with the higher chance of trans-
plant success, in addition to being those who have 
waited longer for a graft 5. Equitable patient treatment 
means to treat differently what is different; hence, 
equity in access to kidney transplantation lies in the 
balance between fairness and efficiency in organ 
distribution.
 AIM
The aim of this work is to evaluate and compare 
three models for deceased donor kidney allocation. 
The first model is adapted directly from the scoring 
criteria of the Portuguese regulations in ordinance n.º 
6537/2007; the second based on the criteria used by 
the ET system6 and the third adapted from the United 
Kingdom kidney allocation system7.
 METHODS
In this analysis, we generated data to simulate a 
waiting list of 500 renal transplant candidates. For each 
of these simulated patients we assigned an age, time 
on dialysis, blood group, human leukocyte antigen (HLA) 
system typing for A*, B* and DRB1* loci, and anti-HLA 
antibodies to impute the respective Panel Reactive 
Antibody calculated value (cPRA)8. We generated these 
data as described elsewhere9. Briefly, we assigned 
transplant candidates’ typing, taking into account pub-
lished HLA allelic and haplotype frequencies10. We 
choose blood groups so that 43% were from group A, 
3% from group AB, 8% from group B and the rest from 
group 0. Further, we assigned Anti-HLA antibodies so 
that 4.6% had a cPRA ≥ 85%; 8.6% a cPRA value between 
50% and 85%; 6.8% a cPRA between 0% and 50% and 
the remaining 80% of the candidates a cPRA equal to 
0%. With these data, we classified candidates with cPRA 
values higher than 85% as belonging to the Acceptable 
Mismatch (AM) Program.
Data were also generated for 70 simulated deceased 
donors9 to be distributed by the best candidates on 
the waiting list according to kidney allocation rules used 
in Portugal, the ET and United Kingdom. Briefly, we 
generated donors’ ages from a normal distribution with 
mean 55 and standard deviation 15; blood groups of 
each donor were randomly assigned, taking into 
account distributions published from Portuguese blood 
donors11 and we generated the respective HLA typing 
randomly from published allelic and haplotype frequen-
cies10 of voluntary bone marrow donors12.
For the three models and for each donor, we selected 
only those candidates without donor specific antibodies 
(negative virtual crossmatch) and AB0 blood group 
compatible. The methods used for candidates’ selection 
through the first model, Portuguese (PT) kidney alloca-
tion system (KAS) (Table I), are described in detail 
elsewhere9.
For the second model, ET KAS (Figure 1), we selected 
only candidates within the Eurotransplant Senior (ES) 
program (i.e., older than 65 years), with a negative 
virtual crossmatch (vXM) and AB0 identical. From these 
we selected the two candidates with longer time on 
dialysis. When the donor was less than 65 years old, 
selected candidates were those within the AM program 
with a negative vXM and AB0 compatible with at least 
0 mismatches for locus DRB1* (MM-DRB1) or 1 MM-
DRB1 and 0/1 mismatches for locus B* (MM-B). Only 
if there were no AM program candidates available did 
we select from the remaining candidates those AB0 
identical. Afterwards we scored candidates according 
to the ET-KAS (Table II) – we calculated mismatch prob-
abilities (MMP) taking into consideration HLA allelic 
frequencies from Portuguese bone marrow donors 10 
and AB0 blood group type frequencies from Portuguese 
blood donors11. We marked the two candidates with 
Table I
Scoring from Ordinance n.º 6357/2007 (PT model)
Criteria Points
HLA Mismatches*
 a) Without MM for HLA-A, B and DR
 b) Without MM for HLA-B and DR 
 c) One MM for HLA-B or DR
 d) One MM for HLA-B and one for HLA-DR
 e) Others
12
8
4
2
1
cPRA ≥ 85%
cPRA ≥ 50%
8
4
Time on dialysis (each month) 0.1
Age difference between donor and receptor
 Donor > 60 and receptor < 55
 Donor < 40 and receptor > 55
 Remaining possibilities
0
0
4
* Mismatches for HLA-A locus are used to break punctual ties;
HLA human leukocyte antigens
cPRA calculated Panel Reactive Antibodies
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higher score as transplanted. This process was repeated 
with the remaining donors until we reached a pool of 
140 transplanted patients.
With the same 500 waitlist candidates and the same 
70 donors, we applied the United Kingdom kidney allo-
cation system (UK-KAS). In this third model, for the first 
donor we selected candidates with a negative vXM and 
AB0 identical (with the exception of AB candidates who 
can receive from A donors and B candidates who can 
receive from 0 donors). We prioritized these patients 
over candidates with 000 mismatches for HLA-A*, -B*, 
DRB1* (MM-HLA) and cPRA ≥85% or homozygotes for 
DRB1* (Figure 2), followed by candidates with 000 MM-
HLA, followed by the remaining candidates according 
to the score assigned by UK-KAS (Table III). Using this 
order, we marked the first two candidates as trans-
planted. We repeated this process with the next donor 
and the remaining candidates until we selected 140 
candidates as transplanted.
Characteristics of candidates selected as transplant-
ed within each one of the models were compared. 
Median time on dialysis, candidates’ ages and differ-
ences between donor and recipient were compared 
Table II
Scoring from EuroTransplant Kidney Allocation System (ET model)
Criteria Points
Number of HLA -A, -B, -DRB1 mismatches
 a) 0
 b) 1
 c) 2
 d) 3
 e) 4
 f) 5
 g) 6
400.00
333.33
266.67
200.00
133.33
66.67
0.00
Mismatch Probability: probability of receiving a kidney offer with 
0/1 mismatch HLA based on 1000 kidneys offered, taking into 
account AB0 blood group rules and cPRA values.
MMP
Time on dialysis (each month) 2.775
HLA human leukocyte antigens
cPRA calculated Panel Reactive Antibodies
MMP mismatch probability
Figure 1
Flow chart for ordering and selection of kidney transplant candidates according to the Euro Transplant kidney 
allocation system.
ES Program Eurotransplant Senior Program
AM Program Acceptable Mismatch Program
ETKAS EuroTransplant Kidney Allocation System
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Table III
Scoring from United Kingdom Kidney Allocation Scheme (UK model)
Criteria Points
HLA mismatches and candidate age
 level 1 (000 MM)
 level 2 (0 MM-DRB1 and 0/1 MM-B)
  level 3 ([0 MM-DRB1 and 2 MM-B] or [1 MM-DRB1 
and 0/1 MM-B])
  level 4 ([1 MM-DRB1 and 2 MM-B] or [2 MM-DRB1])
3500 / (1+(age/55)5)
2000 / (1+(age/55)5)
500 / (1+(age/55)5)
0
HLA-DRB1 homozygous 500
HLA-B homozygous 100
AB0-B candidates if AB0-0 donor -1000
Donor and candidate ages -½ (age difference)2
Time on dialysis (each month) 30
HLA human leukocyte antigens
MM mismatches for HLA-A,-B,-DRB1
Figure 2
Flowchart for ordering transplant candidates according to United Kingdom 
rules
MM mismatches for HLA-A,-B,-DRB1
HLA human leukocyte antigens
cPRA calculated Panel Reactive Antibodies
UK-KAS United Kingdom Kidney Allocation Scheme
Table IV
Comparison of candidates’ characteristics selected through each one of three analyzed models
model PT model ET model UK
n (%) median (1stQ -3rdQ) n (%) median (1stQ -3rdQ) p* n (%) median (1stQ -3rdQ) p†
age (years) 46 (36.8 – 55) 48 (37 – 61.3) 0.15 42 (35.5 – 53) 0.28
Age difference# 12.5 (6 – 22.3) 10 (3.8 – 20) 0.03 8 (4 – 17) <0.001
TD (months) 67 (51.5 – 81) 62.5 (49 – 79.3) 0.27 65.5 (49 – 80.3) 0.63
AB0 blood group
 A
 AB
 B
 0
64 (45.7)
6 (4.3)
12 (8.6)
58 (41.4)
68 (48.6)
6 (4.3)
12 (8.6)
54 (38.6)
64 (45.7)
6 (4.3)
12 (8.6)
58 (41.4)
MM-HLA
 0
 1
 2
 3
 4
 5
 6
0 (0.0)
8 (5.7)
21 (15)
31 (22.1)
42 (30)
24 (17.1)
14 (10)
1 (0.7)
13 (9.3)
36 (25.7)
52 (37.1)
21 (15.0)
16 (11.4)
1 (0.7)
0 (0.0)
9 (6.4)
33 (23.6)
41 (29.3)
30 (21.4)
16 (11.4)
11 (7.9)
Up to 3 MM-HLA 60 (42.9) 102 (72.8) <0.001 83 (59.3) 0.01
More than 3 MM-HLA 80 (57.1) 38 (27.1) 57 (40.7)
mmBDR
 0
 1
 2
 3
 4
7 (5)
34 (24.3)
35 (25)
38 (27.1)
26 (18.6)
3 (2.1)
39 (27.9)
64 (45.7)
23 (16.4)
11 (7.9)
2 (1.4)
55 (39.3)
47 (33.6)
16 (11.4)
20 (14.3)
Up to 2 MM-BDR 76 (54.3) 106 (75.7) <0.001 104 (74.3) <0.001
More than 2 MM-BDR 64 (45.7) 34 (24.3) 36 (25.7)
cPRA
 [0;50[
 [50;85[
 ≥85
82 (58.6)
37 (26.4)
21 (15)
115 (82.1)
10 (7.1)
15 (10.7) 0.37
123 (87.9)
13 (9.3)
4 (2.9) <0.001
* p value for the comparison between model PT and model ET
† p value for the comparison between model PT and model UK
# age difference in years between donor and selected candidate
Q quartile; TD time on dialysis; HLA human leukocyte antigens; MM-HLA mismatches for HLA-A*, -B* and -DRB1*;
MM-BDR mismatches for HLA-B* and -DRB1*; cPRA calculated Panel Reactive 
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using the Kruskal-Wallis test. The chi-square test (or 
Fisher exact test when appropriate) was used to com-
pare recipients’ rates for the cPRA groups and HLA 
mismatches groups for each model. P-values < 0.05 
were considered statistically significant. We performed 
all statistical analysis and graphic representation with 
RStudio software for R programming language.
 RESULTS
We found no statistically significant differences in 
the ages of selected candidates in each of the three 
models under analysis (Table IV). That said, when we 
calculated age differences between donor and receptor, 
we verified that the Portuguese (PT) model selected 
candidates with higher age differences. Median age 
difference between donor and recipient was 12.5 years 
in the PT model, while the UK model selected candi-
dates with a median age difference of only 8 years (p 
<0.001) and for ET allocation model median age differ-
ence was 10 years (p = 0.03).
The ET model selected candidates with a shorter 
time on dialysis (62.5 months); this result was not sta-
tistically different from median time on dialysis observed 
for the PT model’s recipients (67 months). There are 
no differences to highlight regarding blood group dis-
tributions of selected candidates in each model.
Concerning the HLA mismatches between the select-
ed recipients and their donors, the PT model was the 
one that selected  candidates with more HLA mismatch-
es when compared to the other models. In the PT model 
only 60 (42.9%) recipients had up to 3 MM-HLA, but 
the ET model selected 102 (72.8%, p <0.001) and in 
the UK model, 83 (59.3%, p = 0.01) recipients had at 
most 3 MM-HLA. Furthermore, if we take into consid-
eration only MM for loci B * and DRB1 *, the PT model 
selected more recipients with 0 MM-BDR (7, corre-
sponding to 5%). On the other hand, the PT model 
selected 64 (45.7%) recipients with 3 or 4 MM-BDR 
while the ET model selected only 34 (24.3%, p <0.001) 
and only 36 (25.7%, p <0.001) recipients were selected 
with the UK model.
The PT model was the one that selected a higher 
number of hypersensitized candidates 21 (15%); the 
ET model selected 15 (10.7%; there were no statistically 
significant differences with the PT model) and the UK 
model selected only 4 (2.9%, p <0.001) hypersensitized 
candidates.
 DISCUSSION
The Portuguese KAS chooses waitlist candidates with 
more MM-HLA with the donor than the ET and UK KAS 
does. The number of MM-HLA is associated with an 
increased risk of poorer transplant outcomes13. Addi-
tionally, de novo post transplant donor specific anti 
HLA antibodies due to HLA mismatches at transplanta-
tion are associated to graft failure14. These disadvan-
tages for Portuguese transplant candidates are not 
balanced by the selection of candidates with higher 
time on dialysis when compared with the other two 
models in this analysis (differences statistically not 
significant).
Prior to the implementation of ordinance nº 
6537/2007, in Portugal, deceased donor kidney alloca-
tion was primarily made taking into account the number 
of HLA compatibilities with the donor. After 2007, trans-
planted patients were mainly those with a longer time 
on dialysis15 regardless of the number of HLA compat-
ibilities with the donor. As a matter of fact, the Portu-
guese model does not penalize enough transplant 
candidates with several MM-HLA with their potential 
donors. For instance, a transplant candidate with 6 
MM-HLA has one point on the PT KAS; the same point 
attributed to a candidate with only 2 MM-DRB1* or 
with only 2 MM-B*, and just one point less than a 
candidate with 1 MM-B* and 1 MM-DRB1*. In the cur-
rent immunosuppression era, MM-DRB1* have been 
described as the more relevant HLA mismatches associ-
ated with post-transplant rejection episodes 16. While 
the UK model gives a great weight to MM-DRB1* in its 
scoring criteria, the ET model gives equal weight to the 
MM for HLA-A *, -B * and -DRB1 * loci.
If one of the main goals in the implementation of 
the current PT model was to mitigate the hypersensi-
tized candidates’ waiting time disadvantage17, we veri-
fied that the PT model selected the highest percentage 
of hypersensitized patients (15%) compared to the 
other two models; though the difference between this 
and the ET model is not statistically significant. The 
Eurotransplant KAS applies the AM program which pri-
oritizes hypersensitized candidates; yet the PT KAS gives 
extra points to hypersensitized (8 points) and sensitized 
(4 points) candidates. With these extra points, the PT 
model only selects 58.6% of candidates with a cPRA 
<50%, though by the ET model they are 82.1% and by 
the UK model 87.9%.
In this simulation, for each waitlist candidate, we 
calculated a cPRA, when in fact, under ordinance n.º 
Bruno A Lima, Helena Alves
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6537/2007, Portuguese candidates on the waiting list 
are classified (or not) as sensitized patients, taking 
into account only results from the Panel Reactive Anti-
body by the Complement Dependent Cytotoxicity 
(PRA-CDC) screening method. PRA-CDC results are not 
an accurate gauge of the likelihood of finding an 
incompatible donor18 and are used to underestimate 
the real number of hypersensitized candidates on the 
waiting list19. We calculate PRA-CDC as a quotient of 
the number of individuals whose lymphocytes had a 
positive cytotoxic reaction with a patient serum by 
the total number of tested individuals. Since these 
groups of tested individuals may not be representative 
of potential donors’ HLA profiles and given the lack 
of cytotoxic reactions’ sensitivity, PRA-CDC has been 
replaced by cPRA as a measure of allosensitization 
for waitlist transplant candidates20,21. Inevitably, in 
Portugal, as in the ET and UK models, cPRA values will 
also be implemented as a criterion in the distribution 
of kidneys from deceased donors. When applied, cPRA 
will increase the number of hypersensitized candi-
dates on the waiting list, and if applied to the current 
PT KAS, will dilute the extra score few patients cur-
rently benefit from.
Although there were no statistically significant dif-
ferences for candidates’ ages selected by the models, 
recipients on the PT model were those with greater 
age difference between patients and their respective 
donors. The Eurotransplant KAS has the ES program in 
which donors over 65 are primarily targeted to candi-
dates over 65; the UK KAS assigns penalty points directly 
proportional to the age difference between candidate 
and potential donor, whereas the PT KAS only penalizes 
more extreme cases of age differences between can-
didates and donors, which we verified in the results 
obtained.
Moreover, as the population is aging, in Portugal, 
we expect that more kidneys from elderly people will 
become available in the future. In an equitable kidney 
allocation model, older donors should be targeted pri-
marily at older candidates, so measures similar to those 
of the ES program should be considered instead of the 
current point system used in the PT model. Regardless, 
the ES program does not take into account the MM-HLA 
as a way to reduce the organ ischemia time inherent 
in the distances between the Eurotransplant member 
countries. In Portugal, given geographical dimensions, 
MM-HLA should not be overlooked since the reduction 
in the number of MM-HLA is a factor that can coun-
terbalance the disadvantages associated with an older 
organ22.
The definition of clear and equitable rules for deceased 
donors’ organ allocation can also be used in a better 
distribution of kidneys from living donors. As an illustra-
tion, see the example of a living donor exchange pro-
gram23 where an incompatible donor-receptor pair can 
be exchanged with another two or three incompatibles 
pairs. In these programs, the first criterion for choosing 
the pairings is to maximize the number of possible trans-
plants, but if there are still several possibilities of choice, 
then the criteria applied to allocation of deceased donors 
can be used to resolve those ties24.
 LIMITATIONS
Above all, we must emphasize that we obtained the 
results presented here from simulated data and not 
from real waitlist transplant candidates. The lack of 
open data on renal transplant candidates and on organ 
donors25 does not allow us to make a deeper analysis 
in the application of these kidney allocation models. 
For instance, we couldn’t analyze how the number of 
children, the number of candidates for re-transplan-
tation or multi-organ waitlist candidates can condition 
patients’ selection for a given group of donors. Also, 
the fact that transplant candidates can register on two 
transplant waiting lists (something sui generis to Por-
tuguese candidates26) is not part of our analysis.
Application of deceased donor kidney distribution 
rules depends on detailed knowledge of waitlist trans-
plant candidates and the evolution of these donors’ char-
acteristics. To this end, it is necessary to define systematic 
and objective measures27 that are clinically useful and 
can be scrutinized by all interested parts. Accordingly, 
the PT model, due to its lack of simplicity, transparency 
and equity9, needs to be discussed and evaluated so that 
it can be corrected or at least improved. Here, we seek 
to compare the PT model with two other solidly imple-
mented models (the ET model and the UK model), iden-
tifying possible ways to upgrade the former.
More than 10 years after ordinance 6357/2007 was 
implemented and without relevant changes in this 
period, surely the current state of the art allows us to 
find points we need to correct. Furthermore, we must 
base needed corrections or changes on objective data 
and scientifically on verifiable proven evidences. The 
availability of open data regarding renal transplantation 
activity 25 is a sine qua non for achieving this goal.
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 CONCLUSION
In conclusion, we want to emphasize three main 
ideas. First, the current Portuguese KAS can and should 
be replaced by a more equitable allocation system; 
second, a new KAS with objective and more transparent 
criteria can and must be defined and discussed; and 
third, those with responsibilities for defining and imple-
menting a new KAS, in Portugal, do not need to reinvent 
the wheel. At this point, we should be able to process 
data, compare it with other experiences, looking abroad 
for allocation systems that work and can help us to 
improve and fulfill our purposes.
Disclosure of potential conflicts of interest: none declared
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